However, when anti‐VEGF drugs are used in clinical tumor therapy, blocking VEGF signaling may lead to many common adverse vascular reactions, including hypertension and renal vascular injuries, such as proteinuria and thrombotic microangiopathy.30, 40, 41. The gene discussed is VEGFA; the disease is Genetic thrombotic microangiopathy.